World's First AI-Discovered Drug Reaches Phase III Clinical Trials

Insilico Medicine has launched the first Phase III trial of a drug discovered and designed entirely by artificial intelligence. The drug, Rentosertib, targets idiopathic pulmonary fibrosis — a progressive lung disease with limited treatment options.

Key Takeaways

Insilico Medicine has launched the first Phase III trial of a drug discovered and designed entirely by artificial intelligence.
The drug, Rentosertib, targets idiopathic pulmonary fibrosis — a progressive lung disease with limited treatment options.

AI synthesis3 sources9

In a landmark moment for artificial intelligence in medicine, Insilico Medicine has launched the first-ever Phase III clinical trial of a drug discovered and designed entirely by AI — marking a critical test of whether generative algorithms can deliver real treatments to patients.

The drug, Rentosertib (ISM001-055), targets idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease that causes scarring of the lungs and has limited treatment options. The Phase III trial is a prospective, randomized, double-blind, placebo-controlled study expected to enroll 320 patients across China.

"The Phase III study is designed to determine whether the safety profile and lung-function signal observed in Phase IIa can translate into a statistically significant and clinically meaningful benefit for patients," Insilico Medicine said in a statement.

The journey of Rentosertib represents a paradigm shift. The molecule was discovered using Insilico's Pharma.AI platform, which leverages generative AI, deep learning, and reinforcement learning to identify novel drug targets and design candidate molecules. What traditionally takes a decade or more was accomplished in roughly 30 months from target discovery to Phase I.

Phase IIa results showed encouraging signals: patients receiving the drug experienced a dose-dependent reduction in lung function decline, with the highest dose group showing a 98.4 mL improvement in forced vital capacity (FVC) over 12 weeks compared to placebo.

If successful, Rentosertib would not only be a new treatment for IPF — a disease affecting approximately 3 million people worldwide — but would validate the entire paradigm of AI-driven drug discovery.

The trial runs for 52 weeks, with results expected in late 2027. The implications extend far beyond IPF: Insilico has a pipeline of AI-discovered programs in oncology, immunology, and other fibrotic diseases, and its platform is being licensed by major pharmaceutical companies including Takeda, which signed a $600 million deal earlier this month.

"This is the moment AI drug discovery has been working toward," said industry analysts. "Phase III is where promising science meets the definitive test of clinical efficacy."